← All stocks

ASSEMBLY BIOSCIENCES, INC.

ASMB Net buying
CIK 0001426800 #2862 in the set updated 19 Sep 2026
Bought (120 mo)
$21.67M
out of their own pocket, the only kind of buying there is
Sold (120 mo)
$2.82M
$0.00 on a plan · $1.26M straight out of an exercise
Sold at will
$1.56M
63 of 74 sales
Net
+$18.85M
+$20.11M against sales at will

By person

19 insiders · 91 transactions
4.0×

Jason A. Okazaki holds only 4.0 times base salary in stock. $2.60M of shares against $647.50K in salary for 2025.

Salary from the company's own proxy. The shares are what Jason A. Okazaki last reported holding, valued at $23.25, the price Common Stock was last bought or sold at on the open market here, on 17 Jun 2026.

Insider
Role
Bought
Sold
Net
Holding
Worth
Change
GILEAD SCIENCES, INC. entity
10% owner
$20.10M (3)
+$20.10M
4,977,089
$115.72M
+356.8%
Schornstein Alexander
10% owner
$1.42M (10)
+$1.42M
728,113
$16.93M
Colonno Richard James
EVP & CSO, Virology Ops
$944.10K (2) scheduled
−$944.10K
137,009
$3.19M
+8,621%
Lopatin Uri A
Chief Medical Officer
$622.99K (2)
−$622.99K
632,361
$14.70M
+0.9%
RINGO WILLIAM R
Director
$510.39K (11) scheduled
−$510.39K
17,465
$406.06K
−14.7%
McHutchison John G
Director
$439.00K (10)
−$439.00K
18,347
$426.57K
Okazaki Jason A
CEO and President
$101.15K (14)
−$101.15K
111,916
$2.60M
Small Derek A
Director
$99.55K (2)
+$99.55K
828,791
$19.27M
+30.2%
Papkoff Jacqueline Sybil
SVP-CSO Microbiome
$56.48K (3)
−$56.48K
37,364
$868.71K
Delaney William E IV
Chief Scientific Officer
$52.38K (8)
−$52.38K
45,642
$1.06M
Houghton Michael
Director
$50.00K (1)
+$50.00K
3,202
$74.45K
White Nicole S
Chief Manufacturing Officer
$44.27K (11)
−$44.27K
37,477
$871.34K
Stamm Luisa M
Chief Medical Officer
$24.65K (2)
−$24.65K
40,315
$937.32K
Bjorkquist Jeanette M
PFO and PAO
$14.87K (9)
−$14.87K
14,560
$338.52K
Samar Michael P.
Chief Financial Officer
$9.43K (2)
−$9.43K
77,228
$1.80M
+84.6%
COOPER GRAHAM K
See Remarks
117,500
$2.73M
Russo Thomas Joseph
CFO
54,633
$1.27M
Gaggar Anuj
Chief Medical Officer
28,000
$651.00K
Rollins Thomas E
Chief Development Officer
3,750
$87.19K

No percentages here. This company's share count has moved by a factor of 3.2 over the window, from 6,356,286 to 20,360,596 shares. A split, a merger or a large issue changes what the company is, and a holding measured at one point in that run is not a fraction of it at another.

Insider
Date
Role
Action
Shares
Price
Amount
GILEAD SCIENCES, INC.
8 Aug 2025
10% owner
Buy
2,295,920
no price
Houghton Michael
30 Dec 2024
Director
Buy indirect
3,202
$15.61
$50.00K
GILEAD SCIENCES, INC.
19 Dec 2024
10% owner
Buy
940,499
$21.37
$20.10M
Schornstein Alexander
25 Nov 2024
10% owner
Buy
5,000
$14.85
$74.25K
Schornstein Alexander
25 Nov 2024
10% owner
Buy
2,976
$15.00
$44.64K
Schornstein Alexander
22 Nov 2024
10% owner
Buy
17,024
$14.87
$253.10K
Schornstein Alexander
8 Oct 2024
10% owner
Buy
10,000
$14.58
$145.80K
Schornstein Alexander
5 Jul 2024
10% owner
Buy
4,438
$12.52
$55.56K
Schornstein Alexander
3 Jul 2024
10% owner
Buy
4,562
$12.29
$56.07K
GILEAD SCIENCES, INC.
17 Jun 2024
10% owner
Buy
179,500
no price
Schornstein Alexander
18 Jan 2024
10% owner
Buy
345,086
$0.80
$276.07K
Schornstein Alexander
17 Jan 2024
10% owner
Buy
299,994
$0.78
$235.20K
Schornstein Alexander
21 Nov 2023
10% owner
Buy
100,000
$0.67
$66.70K
Schornstein Alexander
20 Nov 2023
10% owner
Buy
300,000
$0.72
$215.40K
Small Derek A
19 Jul 2018
CEO and President
Buy
1,200
$41.77
$50.12K
Small Derek A
19 Jul 2018
CEO and President
Buy
1,200
$41.19
$49.43K

What was left out

Form 4 filings counted 216
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 11
Sales at will 63
Transactions with no price 2
Shares from compensation/vesting 2,227,303
Sales filed before the plan box existed 21
History held since 31 Mar 2017